Refine
Has Fulltext
- yes (36)
Is part of the Bibliography
- yes (36)
Year of publication
Document Type
- Journal article (36) (remove)
Language
- English (36)
Keywords
- echocardiography (7)
- myocardial infarction (6)
- heart failure (5)
- impact (3)
- inflammation (3)
- mortality (3)
- prognosis (3)
- Germany (2)
- TAVI (2)
- acute heart failure (2)
- amyloidosis (2)
- cardiomyopathy (2)
- cardiovascular magnetic resonance (2)
- chronic kidney disease (2)
- deformation (2)
- depression (2)
- ejection fraction (2)
- heart (2)
- left ventricular ejection fraction (2)
- morbidity (2)
- multicenter (2)
- outcomes (2)
- replacement (2)
- sizing (2)
- therapy (2)
- 2-dimensional speckle tracking (1)
- ACC/AHA classification (1)
- ARDS (acute respiratory distress syndrome) (1)
- Anderson-Fabry Disease (1)
- B cells (1)
- COPD diagnosis (1)
- COVID-19 (1)
- CardioMEMS™ HF system (1)
- Cardiovascular magnetic-resonance (1)
- Chronic heart-failure (1)
- Coronary artery disease (1)
- D313Y genotype (1)
- Desmoplakin (1)
- Disaster response (1)
- Enzyme replacement therapy (1)
- Fabry cardiomyopathy (1)
- Fabry disease (1)
- Fabry nephropathy (1)
- Fabry-associated pain (1)
- GOLD (1)
- Guidelines (1)
- Hospital emergency plan (1)
- Hypertrophic cardiomyopathy (1)
- Impella (1)
- Juvenile biventricular cardiomyopathy (1)
- Management (1)
- Manifestation (1)
- Mass critical care (1)
- Medizin (1)
- Myocardial fibrosis (1)
- Non‐ischaemic cardiogenic shock (1)
- Pain (1)
- Palmoplantar keratoderma (1)
- Prevalence (1)
- Prognostic impact (1)
- Risk-factors (1)
- SARS-CoV-2 (1)
- SCORE (1)
- ST-elevation myocardial infarction (1)
- Septal bulge (1)
- T cells (1)
- Task force (1)
- Valvular heart-desease (1)
- Ventricular-arrhythmias (1)
- accelerated atherosclerosis (1)
- adaptive immune response (1)
- anaemia (1)
- anatomy (1)
- aneurysm (1)
- anti-myocardial (1)
- antibodies (1)
- anxiety (1)
- aortic valve stenosis (AS) (1)
- apolipoprotein E (1)
- apoptosis (1)
- arterial stiffening (1)
- atherosclerosis (1)
- autoantibody (1)
- awareness (1)
- biomarker (1)
- blood (1)
- blood coagulation factor XIII (1)
- blood pressure monitoring (1)
- body weight (1)
- bull’s eye plot (1)
- calcification (1)
- calcium imaging (1)
- cardiac amyloidosis (1)
- cardiac magnetic resonance imaging (1)
- cardiac transplantation (1)
- cardiac ventricles (1)
- carotid artery disease (1)
- case report (1)
- chronic heart failure (1)
- clinical manifestations (1)
- comorbidity (1)
- complex (1)
- coronary artery disease (1)
- coronary heart disease (1)
- cryptogenic stroke (1)
- cytokines (1)
- death rates (1)
- deficient mice (1)
- diagnosis (1)
- diagnostic medicine (1)
- diastolic dysfunction (1)
- dimensions (1)
- disease (1)
- dobutamine stress echocardiography (1)
- double knockout mice (1)
- endothelial cell interactions (1)
- enzyme-linked immunoassays (1)
- euroaspire (1)
- extracellular matrix (1)
- extracellular matrix remodeling (1)
- fabry disease (1)
- fatal cardiovascular disease (1)
- fibrosis (1)
- guideline adherence (1)
- guideline implementation (1)
- guidelines (1)
- haemodynamic monitoring (1)
- healing and remodelling processes (1)
- health care (1)
- health‐related quality of life (1)
- heart disease (1)
- heart failure with mid-range ejection fraction (1)
- heart failure with reduced ejection fraction (1)
- heart rate (1)
- hypertension (1)
- hypertrophic cardiomyopathy (1)
- identification (1)
- in vivo (1)
- inherited metabolic disorders (1)
- intensive care medicine (1)
- kidneys (1)
- left ventricular hypertrophy (1)
- left ventricular thrombusv (1)
- lesion formation (1)
- leukocyte adhesion (1)
- lipoxygenase (1)
- low-gradient AS (1)
- lower limit of normal (1)
- magnetic resonance imaging (1)
- management (1)
- memory B cells (1)
- mice (1)
- mild (1)
- mineralocorticoid antagonist (1)
- multidetector computed-tomography (1)
- myocardial fibrosis (1)
- myocardium (1)
- natriuretic peptide (1)
- neutrophils (1)
- nitric oxide synthase (1)
- pandemia (1)
- paravalvular regurgitation (1)
- pharmacotherapy (1)
- platelet adhesion (1)
- preserved ejection fraction (1)
- pseudo-severe AS (1)
- public health (1)
- quality of life (1)
- recommendations (1)
- recovery (1)
- regression analysis (1)
- regurgitation (1)
- right ventricular dysfunction (1)
- root (1)
- sex differences (1)
- speckle tracking imaging (1)
- statins (1)
- stem cell transplantation (1)
- stenosis (1)
- surgical and invasive medical procedures (1)
- tomography (1)
- troponin T (1)
- validation (1)
- vascular surgery (1)
Institute
- Medizinische Klinik und Poliklinik I (32)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (14)
- Institut für Klinische Epidemiologie und Biometrie (5)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (5)
- Institut für Pharmakologie und Toxikologie (3)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (3)
- Medizinische Klinik und Poliklinik II (3)
- Institut für Virologie und Immunbiologie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (2)
Background: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factorinducible 14 (Fn14) are upregulated after myocardial infarction (MI) in both humans and mice. They modulate inflammation and the extracellular matrix, and could therefore be important for healing and remodeling after MI. However, the function of TWEAK after MI remains poorly defined.
Methods and results: Following ligation of the left coronary artery, mice were injected twice per week with a recombinant human serum albumin conjugated variant of TWEAK (HSA-Flag-TWEAK), mimicking the activity of soluble TWEAK. Treatment with HSA-Flag-TWEAK resulted in significantly increased mortality in comparison to the placebo group due to myocardial rupture. Infarct size, extracellular matrix remodeling, and apoptosis rates were not different after MI. However, HSA-Flag-TWEAK treatment increased infiltration of proinflammatory cells into the myocardium. Accordingly, depletion of neutrophils prevented cardiac ruptures without modulating all-cause mortality.
Conclusion: Treatment of mice with HSA-Flag-TWEAK induces myocardial healing defects after experimental MI. This is mediated by an exaggerated neutrophil infiltration into the myocardium.
Early healing after myocardial infarction (MI) is characterized by a strong inflammatory reaction. Most leukotrienes are pro-inflammatory and are therefore potential mediators of healing and remodeling after myocardial ischemia. The enzyme 5-lipoxygenase (5-LOX) has a key role in the transformation of arachidonic acid in leukotrienes. Thus, we tested the effect of 5-LOX on healing after MI. After chronic coronary artery ligation, early mortality was significantly increased in 5-LOX\(^{−/−}\) when compared to matching wildtype (WT) mice due to left ventricular rupture. This effect could be reproduced in mice treated with the 5-LOX inhibitor Zileuton. A perfusion mismatch due to the vasoactive potential of leukotrienes is not responsible for left ventricular rupture since local blood flow assessed by magnetic resonance perfusion measurements was not different. However, after MI, there was an accentuation of the inflammatory reaction with an increase of pro-inflammatory macrophages. Yet, mortality was not changed in chimeric mice (WT vs. 5-LOX\(^{−/−}\) bone marrow in 5-LOX\(^{−/−}\) animals), indicating that an altered function of 5-LOX\(^{−/−}\) inflammatory cells is not responsible for the phenotype. Collagen production and accumulation of fibroblasts were significantly reduced in 5-LOX\(^{−/−}\) mice in vivo after MI. This might be due to an impaired migration of 5-LOX\(^{−/−}\) fibroblasts, as shown in vitro to serum. In conclusion, a lack or inhibition of 5-LOX increases mortality after MI because of healing defects. This is not mediated by a change in local blood flow, but through an altered inflammation and/or fibroblast function.
Despite recent therapeutic advances the prognosis of heart failure remains poor. Recent research suggests that heart failure is a heterogeneous syndrome and that many patients have stimulating auto-antibodies directed against the second extracellular loop of the \(β_1\) adrenergic receptor \((β_1EC2)\). In a human-analogous rat model such antibodies cause myocyte damage and heart failure. Here we used this model to test a novel antibody-directed strategy aiming to prevent and/or treat antibody-induced cardiomyopathy. To generate heart failure, we immunised n = 76/114 rats with a fusion protein containing the human β1EC2 (amino-acids 195–225) every 4 weeks; n = 38/114 rats were control-injected with 0.9% NaCl. Intravenous application of a novel cyclic peptide mimicking \(β_1EC2\) (\(β_1EC2-CP\), 1.0 mg/kg every 4 weeks) or administration of the \(β_1-blocker\) bisoprolol (15 mg/kg/day orally) was initiated either 6 weeks (cardiac function still normal, prevention-study, n = 24 (16 treated vs. 8 untreated)) or 8.5 months after the 1st immunisation (onset of cardiomyopathy, therapy-study, n = 52 (40 treated vs. 12 untreated)); n = 8/52 rats from the therapy-study received \(β_1EC2-CP/bisoprolol\) co-treatment. We found that \(β_1EC2-CP\) prevented and (alone or as add-on drug) treated antibody-induced cardiac damage in the rat, and that its efficacy was superior to mono-treatment with bisoprolol, a standard drug in heart failure. While bisoprolol mono-therapy was able to stop disease-progression, \(β_1EC2-CP\) mono-therapy -or as an add-on to bisoprolol- almost fully reversed antibody-induced cardiac damage. The cyclo¬peptide acted both by scavenging free \(anti-β_1EC2-antibodies\) and by targeting \(β_1EC2\)-specific memory B-cells involved in antibody-production. Our model provides the basis for the clinical translation of a novel double-acting therapeutic strategy that scavenges harmful \(anti-β_1EC2-antibodies\) and also selectively depletes memory B-cells involved in the production of such antibodies. Treatment with immuno-modulating cyclopeptides alone or as an add-on to \(β_1\)-blockade represents a promising new therapeutic option in immune-mediated heart failure.
Background: Depression and anxiety are common and independent outcome predictors in patients with chronic heart failure (CHF). However, it is unclear whether CHF causes depression. Thus, we investigated whether mice develop anxiety- and depression-like behavior after induction of ischemic CHF by myocardial infarction (MI).
Methods and Results: In order to assess depression-like behavior, anhedonia was investigated by repeatedly testing sucrose preference for 8 weeks after coronary artery ligation or sham operation. Mice with large MI and increased left ventricular dimensions on echocardiography (termed CHF mice) showed reduced preference for sucrose, indicating depression-like behavior. 6 weeks after MI, mice were tested for exploratory activity, anxiety-like behavior and cognitive function using the elevated plus maze (EPM), light-dark box (LDB), open field (OF), and object recognition (OR) tests. In the EPM and OF, CHF mice exhibited diminished exploratory behavior and motivation despite similar movement capability. In the OR, CHF mice had reduced preference for novelty and impaired short-term memory. On histology, CHF mice had unaltered overall cerebral morphology. However, analysis of gene expression by RNA-sequencing in prefrontal cortical, hippocampal, and left ventricular tissue revealed changes in genes related to inflammation and cofactors of neuronal signal transduction in CHF mice, with Nr4a1 being dysregulated both in prefrontal cortex and myocardium after MI.
Conclusions: After induction of ischemic CHF, mice exhibited anhedonic behavior, decreased exploratory activity and interest in novelty, and cognitive impairment. Thus, ischemic CHF leads to distinct behavioral changes in mice analogous to symptoms observed in humans with CHF and comorbid depression.
Objectives: Since diastolic abnormalities are typical findings of cardiac amyloidosis (CA), we hypothesized that speckle-tracking-imaging (STI) derived longitudinal early diastolic strain rate (LSRdias) could predict outcome in CA patients with preserved left ventricular ejection fraction (LVEF >50%).
Background: Diastolic abnormalities including altered early filling are typical findings and are related to outcome in CA patients. Reduced longitudinal systolic strain (LSsys) assessed by STI predicts increased mortality in CA patients. It remains unknown if LSRdias also related to outcome in these patients.
Methods: Conventional echocardiography and STI were performed in 41 CA patients with preserved LVEF (25 male; mean age 65±9 years). Global and segmental LSsys and LSRdias were obtained in six LV segments from apical 4-chamber views.
Results: Nineteen (46%) out of 41 CA patients died during a median of 16 months (quartiles 5–35 months) follow-up. Baseline mitral annular plane systolic excursion (MAPSE, 6±2 vs. 8±3 mm), global LSRdias and basal-septal LSRdias were significantly lower in non-survivors than in survivors (all p<0.05). NYHA class, number of non-cardiac organs involved, MAPSE, mid-septal LSsys, global LSRdias, basal-septal LSRdias and E/LSRdias were the univariable predictors of all-cause death. Multivariable analysis showed that number of non-cardiac organs involved (hazard ratio [HR] = 1.96, 95% confidence interval [CI] 1.17–3.26, P = 0.010), global LSRdias (HR = 7.30, 95% CI 2.08–25.65, P = 0.002), and E/LSRdias (HR = 2.98, 95% CI 1.54–5.79, P = 0.001) remained independently predictive of increased mortality risk. The prognostic performance of global LSRdias was optimal at a cutoff value of 0.85 S−1 (sensitivity 68%, specificity 67%). Global LSRdias <0.85 S−1 predicted a 4-fold increased mortality in CA patients with preserved LVEF.
Conclusions: STI-derived early diastolic strain rate is a powerful independent predictor of survival in CA patients with preserved LVEF.
Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) defines COPD as a fixed postbronchodilator ratio of forced expiratory volume in 1 second and forced vital capacity (FEV1/FVC) below 0.7. Agedependent cut-off values below the lower fifth percentile (LLN) of this ratio derived from the general population have been proposed as an alternative. We wanted to assess the diagnostic accuracy and prognostic capability of the GOLD and LLN definition when compared to an expert-based diagnosis. Methods: In a prospective cohort study, 405 patients aged ≥ 65 years with a general practitioner’s diagnosis of COPD were recruited and followed up for 4.5 (median; quartiles 3.9; 5.1) years. Prevalence rates of COPD according to GOLD and three LLN definitions and diagnostic performance measurements were calculated. The reference standard was the diagnosis of COPD of an expert panel that used all available diagnostic information, including spirometry and bodyplethysmography. Results: Compared to the expert panel diagnosis, ‘GOLD-COPD’ misclassified 69 (28%) patients, and the three LLNs misclassified 114 (46%), 96 (39%), and 98 (40%) patients, respectively. The GOLD classification led to more false positives, the LLNs to more false negative diagnoses. The main predictors beyond the FEV1/FVC ratio for an expert diagnosis of COPD were the FEV1 % predicted, and the residual volume/total lung capacity ratio (RV/TLC). Adding FEV1 and RV/TLC to GOLD or LLN improved the diagnostic accuracy, resulting in a significant reduction of up to 50% of the number of misdiagnoses. The expert diagnosis of COPD better predicts exacerbations, hospitalizations and mortality than GOLD or LLN. Conclusions: GOLD criteria over-diagnose COPD, while LLN definitions under-diagnose COPD in elderly patients as compared to an expert panel diagnosis. Incorporating FEV1 and RV/TLC into the GOLD-COPD or LLN-based definition brings both definitions closer to expert panel diagnosis of COPD, and to daily clinical practice.